stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) Current ratio
Aurinia Pharmaceuticals Inc's current ratio at the end of the quarter to 30 September 2026 was 6.1×, up 0.9× from fiscal 2025 (5.2×). Over the past ten years it has ranged from 4.6× (fiscal 2024) to 27.9× (fiscal 2019); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.2× | 14.91% |
| FY2024 | 4.6× | (16.99%) |
| FY2023 | 5.5× | (42.66%) |
| FY2022 | 9.6× | (24.00%) |
| FY2021 | 12.6× | (3.66%) |
| FY2020 | 13.1× | (53.02%) |
| FY2019 | 27.9× | 52.49% |
| FY2018 | 18.3× | (14.91%) |
| FY2017 | 21.5× | 311.70% |
| FY2016 | 5.2× | 14.26% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 6.1× | 13.00% |
| Jun 2026 | 5.4× | (2.33%) |
| Mar 2026 | 5.5× | 5.70% |
| Dec 2025 | 5.2× | (8.81%) |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 32.8× |
| PVLA Palvella Therapeutics, Inc. compare | 21.2× |
| IMNM Immunome, Inc. compare | 15.1× |
| CLDX Celldex Therapeutics, Inc. compare | 11.8× |
| VERA Vera Therapeutics, Inc. compare | 10.9× |
| AUPH Aurinia Pharmaceuticals Inc | 6.1× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| VCEL Vericel Corporation compare | 5.1× |
| BHVN Biohaven Ltd. compare | 3.1× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement